Latest News and Press Releases

Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at...

New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallowEvrysdi has demonstrated consistent clinically meaningful efficacy in...

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the...

Data presented at the 2021 ESMO Virtual Congress and the IASLC 2021 WCLC add to the body of evidence supporting Tecentriq’s role in treating early-stage lung cancerAs published in The Lancet,...

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes...

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image...

Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated...

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from...

Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in...

Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1Based...